ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Replek AD Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.	North Macedonia	REPL
Respiratorius AB Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.	Sweden	RESP
REVELATION BIOSCIENCES, INC. Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.	United States of America	REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.	United States of America	RVPH
Revolution Medicines, Inc. A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.	United States of America	RVMD
REVVITY, INC. Provides life sciences & diagnostics technologies to support workflows from discovery to cure.	United States of America	RVTY
REYON PHARMACEUTICAL CO., LTD Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.	South Korea	102460
Rezolute, Inc. Developing therapies for rare metabolic diseases, focusing on hyperinsulinism-caused hypoglycemia.	United States of America	RZLT
RHYTHM PHARMACEUTICALS, INC. Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.	United States of America	RYTM
RIGEL PHARMACEUTICALS INC Develops and commercializes small-molecule drugs for hematology, cancer, and autoimmune diseases.	United States of America	RIGL